[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"functional-magnetic-resonance-imaging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:functional-magnetic-resonance-imaging":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,70,97,129,154,180,212],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100574300","lf-rtms-attenuates-visceral-pain-in-irritable-bowel-syndrome-with-diarrhea-100574300",false,"NCT06757491","Lf-rTMS Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea","Low-frequency Repetitive Transcranial Magnetic Stimulation Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea Via Inhibition of the Medial Prefrontal Cortex","All diagnoses were made by board-certified gastroenterologists. Eligible participants met the following inclusion criteria: (1) age between 18 and 75 years; (2) fulfillment of the Rome IV diagnostic criteria for IBS-D. Exclusion criteria included: (1) presence of inflammatory or other organic gastrointestinal diseases; (2) diagnosed psychiatric disorders; (3) history of anorectal, intestinal, or abdominal surgery; (4) pregnancy or lactation; (5) presence of metallic implants or cardiac pacemakers.","ALL","18 Years","75 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"NA","Objectives: To identify a central hub of visceral pain in IBS-D and elucidate the mechanism by which repetitive transcranial magnetic stimulation (rTMS) confers analgesic effects.\n\nMethods: A total of 42 IBS-D patients were recruited and randomly assigned (1:1) to the sham rTMS or the rTMS group. A nested cohort of 21 IBS-D participants who completed baseline fMRI assessments prior to randomization was included. Consistent with the randomization procedure，these individuals were evenly distributed between the two groups. Both participants and outcome assessors remained blinded to treatment allocation throughout the study. All patients completed the two-week intervention and were included in the final analysis.",[27,28,29,30,31],"Repetitive Transcranial Magnetic Stimulation","Chronic Visceral Pain","Functional Magnetic Resonance Imaging","IBS (Irritable Bowel Syndrome)","Clinical Efficacy","RECRUITING","2025-11-18",{"date":35,"type":36},"2025-11-21","ACTUAL",{"date":38,"type":36},"2024-08-01",{"date":40,"type":21},"2026-01-25",{"name":42,"class":43},"The First Affiliated Hospital of Soochow University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100545023","effects-of-tdcs-for-enhancing-cognitive-function-in-individuals-with-persistent-post-concussion-syndrome-100545023","NCT06376500","Effects of tDCS for Enhancing Cognitive Function in Individuals With Persistent Post-Concussion Syndrome","Effects of Transcranial Direct Current Stimulation for Enhancing Cognitive Function in Individuals With Persistent Post-Concussion Syndrome: A Pilot fMRI\u002F1H-MRS Study","Inclusion Criteria:\n\n* being 18 years old or older;\n* having a history of a mild TBI (less than 30 minutes loss of consciousness) 1-6 years prior to the study;\n* able to communicate in Chinese.\n\nExclusion Criteria:\n\n* being without a confirmed diagnosis from the medical practitioner;\n* having a history of other neurological and psychiatric disorders, skull defect, recent medical instability (within 3 weeks);\n* being pregnant;\n* being medication for a psychiatric condition (e.g., major depression, anxiety, schizophrenia);\n* with any implanted devices or suffering from real claustrophobia or feel uncomfortable in small, enclosed spaces, like MRI tunnel","65 Years",{"count":54,"type":21},40,[24],"Globally, 10 million new traumatic brain injury (TBI) cases are estimated annually, with mild traumatic brain injury (mTBI) accounting for 75-90% of all TBI cases. It is estimated that 40-80% of individuals with mTBI may experience the post-concussion syndrome (PCS), which is characterized by a range of physical, cognitive, and emotional symptoms. Although the underlying basis of cognitive dysfunction of patients with persistent PCS remains to be clarified, converging evidence shows that the clinical symptoms is underpinned by abnormal neural information processing as a result of axonal injury due to mTBI. Recent studies have demonstrated abnormalities in both structural and functional cortical connectivity, and a loss of cortical excitability-inhibitory (E\u002FI) balance after TBI. Yet, there is no consensus for treating chronic symptoms of concussion, and PCS remains a chronic and highly disabling condition. One potential treatment option is transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique that has been shown to modify behavior by enhancing connectivity between targeted brain areas. However, research on the therapeutic effect of tDCS on PCS symptoms is limited, and the neurologic mechanisms underlying its effects are not well understood. The proposed study aims to address these knowledge gaps by examining the effects of tDCS on the central nervous system function in patients with PCS, with a specific focus on functional cortical connectivity and cognitive functions such as processing speed and executive function. The study also aims to add value to existing evidence by potentially opening new directions for designing intervention programs for the treatment of PCS after mTBI.",[58,59,29,60],"Transcranial Direct Current Stimulation","Post-Concussion Syndrome","Magnetic Resonance Spectroscopy","2025-09-18",{"date":63,"type":36},"2025-09-19",{"date":65,"type":36},"2025-09-01",{"date":67,"type":21},"2028-02",{"name":69,"class":43},"The Hong Kong Polytechnic University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100583093","the-clinical-study-of-synaptic-plasticity-based-lencanumab-for-the-treatment-of-early-alzheimers-disease-100583093","NCT06871839","The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease","Inclusion Criteria:\n\n1. Age between 50 and 90 years.\n2. Male or female patients.\n3. Patients with MCI and mild AD.\n4. MMSE score ≥20, CDR overall score of 0.5 or 1.\n5. Amyloid-positive confirmed by Amyloid-PET or CSF.\n6. Have a reliable caregiver to accompany the patient during study visits and supervise the use of study medication during the trial.\n7. Agree to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with cognitive impairment due to reasons other than AD.\n2. A history of transient ischemic attack (TIA), stroke, cerebral hemorrhage, or seizure within the 12 months prior to screening.\n3. A score of \\>17 on the Hamilton Depression Scale at screening, or any suicidal behavior within 6 months prior to screening, at screening, or at the baseline visit, as well as any psychiatric diagnosis or symptoms that interfere with the study procedure (such as hallucinations, anxiety disorder, or paranoia).\n4. Patients with a bleeding disorder or receiving anticoagulant therapy, as well as any with malignant tumors, severe gastrointestinal, kidney, liver, respiratory, immune, endocrine, and cardiovascular system diseases that affect this study.\n5. A hypersensitivity reaction to ranucimab or any other ingredient in the injection solution, or to any monoclonal antibody treatment.\n6. Contraindications to MRI scanning, including those with a pacemaker\u002Fdefibrillator or ferromagnetic metal implants (except for skull and cardiac devices approved as safe for MRI scanning).\n7. A known or suspected history of drug or alcohol abuse or dependence within the 2 years prior to screening.\n8. Participation in a clinical study involving any therapeutic monoclonal antibody or novel compounds for the treatment of AD within the 6 months prior to screening, unless it can be proven that the subject was in the placebo treatment group.\n9. Planning to undergo surgery requiring general anesthesia during the study period.\n10. A positive pregnancy test result, lactation, or pregnancy in females at screening or baseline.","50 Years","90 Years",{"count":79,"type":21},120,"OBSERVATIONAL","Alzheimer's disease (AD) manifests itself in cognitive decline, impaired ability to perform daily life, and a variety of behavioral and psychiatric symptoms, seriously endangering the health of the elderly. The prevalence and disability rates of AD in China remain high, and the lack of effective treatment options has brought a heavy burden to patients and their families. Early intervention is regarded as an effective strategy to improve clinical symptoms, delay disease progression and maintain current quality of life. The humanized monoclonal antibody lencanemab (Lecanemab) was approved by the U.S. FDA in July 2023 for the treatment of mild cognitive impairment or mild dementia caused by AD, and was officially approved in January 2024 in China. Lencanemab highly targets soluble and insoluble neurotoxic β-amyloid (Aβ) proteins, reducing pathogenic Aβ plaque deposition and preventing its formation in the brains of AD patients, thus reducing neurotoxicity and improving patients' cognitive functions. In addition, lencanumab may also play a neuroprotective role by modulating synaptic plasticity and regulating neural network activity in brain neurons. However, there is a lack of clinical studies to prove this mechanism. In this study, we will enroll consecutive patients with early AD treated with lencanemab infusion as well as those receiving conventional anti-dementia therapy, and comprehensively assess the effects and intrinsic molecular mechanisms of lencanemab on synaptic function and neural networks using magnetic resonance imaging, molecular imaging positron emission tomography (PET), neuropsychological assessment, and analysis of blood cerebrospinal fluid samples.",[83,84,29],"Alzheimer's Disease","Lecanemab",[86,84,87],"Alzheimer's disease","functional magnetic resonance imaging","2025-07-19",{"date":90,"type":36},"2025-07-22",{"date":92,"type":36},"2025-03-10",{"date":94,"type":21},"2026-12-31",{"name":96,"class":43},"Cuibai Wei，Clinical Professor",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":44},"100454185","mri-eye-tracking-pairing-a-tool-for-assessing-social-cognition-in-children-with-asd-100454185","NCT05194254","MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD","IRM-ET","Inclusion Criteria:\n\nFor the group of people with Autism Spectrum Disorders (experimental group):\n\n* Age between 10 to 20 years old\n* Diagnosis of ASD (CARS) ≥ 30 performed at inclusion\n* IQ test evaluation (regardless of the result) performed by a trained psychologist\n* Obtaining informed oral and written consent after appropriate information\n* Obtaining informed oral and written consent from the legal guardian after information\n* Be affiliated with social security\n* No contraindication to magnetic resonance imaging\n\nFor the TD (Typical Development) group of people (control group):\n\n* Age between 10 to 20 years old\n* Diagnosis of ASD (CARS) \\\u003C30 performed at inclusion\n* IQ test evaluation (regardless of the result) performed by a trained psychologist\n* Obtaining informed oral and written consent after appropriate information\n* Obtaining informed oral and written consent from the legal guardian after information\n* Be affiliated with social security\n* No contraindication to magnetic resonance imaging\n\nExclusion Criteria:\n\nFor all groups:\n\n* Age outside the range 10 to 20 years\n* Person with a contraindication to MRI (including claustrophobia, pace maker, neurosurgical clips, vascular clips, heart valves, ventriculoperitoneal valves, cochlear implant, neurostimulator, intraocular metal shards, joint prosthesis, etc.)\n* Person suffering from major obesity (\\> 140 kg) not allowing him to enter the tunnel of the MRI machine (diameter \\\u003C70cm)\n* Pregnant or breastfeeding woman\n* Person under guardianship or guardianship or deprived of liberty by a judicial or administrative decision\n\nFor TD people (control group):\n\n* Person with psychiatric disorders such as attention disorder with or without hyperactivity, depression, bipolar disorder and schizophrenia.\n* Person with a neurological history such as epilepsy and \u002F or neurovascular accident.",true,"10 Years","20 Years",{"count":108,"type":21},68,[24],"Most studies use static visual percepts that are less representative of joint attention versus an ecological environment. This has the consequence of decreasing the perception of an interaction with a social partner, which is an essential step in achieving joint attention. The originality of this study is to improve the design of visual percepts (in the form of video) in order to mimic an ecological environment as much as possible by using MRI-ET coupling. The second originality of this study is the longitudinal exploration of the neurodevelopment of social cognition in autistic children. Studies by the Redcay and Oberwelland teams observe different activations at different ages. The hypothesis is that the perception of joint attention varies over time in people with ASD. To date, there are no studies to determine the influence of childhood neurodevelopment in autistic people on the perception of joint attention. It would be unprecedented to use the MRI-ET pairing as a tool for assessing social cognition as a function of the development of children with ASD.",[112,29,113,114,115],"ASD","Eye Tracking","Social Cognition","Joint Attention",[112,117,113,118,119],"Functional magnetic resonance imaging","social cognition","joint attention","2025-05-22",{"date":122,"type":36},"2025-05-28",{"date":124,"type":36},"2022-01-04",{"date":126,"type":21},"2025-06",{"name":128,"class":43},"Centre Hospitalier Universitaire, Amiens",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":104,"sex":16,"minAge":17,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100559481","to-explore-the-functional-connectivity-pattern-of-cortical-swallowing-network-in-the-oral-phase-of-post-stroke-dysphagia-based-on-dynamic-causal-modelling-100559481","NCT06564688","To Explore the Functional Connectivity Pattern of Cortical Swallowing Network in the Oral Phase of Post-stroke Dysphagia Based on Dynamic Causal Modelling","Inclusion Criteria:\n\n1. Inclusion criteria of patients with post-stroke oral dysphagia:\n\n   * Patients with dysphagia after first stroke, meeting the diagnostic criteria of stroke, and confirmed by brain CT or brain MRI;\n   * Oral dysphagia caused by stroke;\n   * FOIS level ≤ 5; WST level ≥3;\n   * Those who can understand and carry out the simple instructions of the treatment staff and are willing to accept the examination and treatment;\n   * Clear consciousness and stable vital signs;\n   * Patients in the recovery stage with stroke course and dysphagia duration between 0 and 6 months;\n   * Right-handed;\n   * Voluntary participants with informed consent.\n2. Inclusion criteria of patients without dysphagia after stroke:\n\n   * Patients with first-ever stroke, meeting the diagnostic criteria of stroke, and confirmed by brain CT or brain MRI;\n   * No dysphagia, FOIS level =7; WST level =1;\n   * Those who can understand and carry out the simple instructions of the treatment staff and are willing to accept the examination and treatment;\n   * Clear consciousness and stable vital signs;\n   * Patients in the recovery stage with stroke duration between 0 and 6 months;\n   * Right-handed;\n   * Voluntary participants with informed consent.\n3. Inclusion criteria of healthy control group:\n\n   * Normal cognitive function and swallowing function, FOIS level =7; WST level =1;\n   * Gender and age matched with patients with dysphagia in the oral phase after stroke;\n   * Right-handed;\n   * Voluntary participants with informed consent.\n\nExclusion Criteria:\n\n* Dysphagia not caused by stroke or non-oral dysphagia;\n* History of cerebral trauma, stroke, brain tumor, cerebrovascular, intracranial infection, Parkinson's disease, epilepsy, or other neurological or psychiatric diseases;\n* Symptoms of severe aphasia, neglect, visual field defect and other cortical lesions; Patients with severe cognitive impairment or depression;\n* Taking or within 2 weeks of taking drugs that affect the nervous system or psychoses;\n* Patients with metal implants and\u002For spatial claustrophobia who are not suitable for MRI scanning;\n* Visual\u002Fhearing disorders affecting training and assessment;\n* Persons who are participating in other research trials that may influence the results of this study.","80 Years",{"count":137,"type":21},72,"Swallowing activity in the oral phase is regulated by the cortical swallowing network, and the functional connectivity pattern of the cortical swallowing network is related to swallowing activity. The structural damage of the cortical swallowing network and abnormal activation of brain areas related to swallowing in post-stroke dysphagia affect swallowing activity. The recovery of dysphagia after stroke is related to the compensation of swallowing network in the contralateral hemisphere and different connectivity patterns of diseased brain areas, and the integrity of cortical swallowing network connectivity affects the sequence of oral swallowing activities. However, it is not clear how the functional connectivity patterns and interactions of brain regions of the cortical swallowing network related to oral swallowing activity change in patients with oral dysphagia after stroke.",[140,141,29,142,143],"Dysphagia After Stroke","Cortical Swallowing Network","Oral Phase","Dynamic Causal Modelling","NOT_YET_RECRUITING","2024-08-19",{"date":147,"type":36},"2024-08-21",{"date":149,"type":21},"2024-08-20",{"date":151,"type":21},"2025-07-01",{"name":153,"class":43},"Fujian University of Traditional Chinese Medicine",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":169,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":44},"100534679","high-definition-transcranial-direct-current-stimulation-hd-tdcs-for-refractory-epilepsy-100534679","NCT06241963","High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy","The Efficacy, Safety and Mechanism of High Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Refractory Epilepsy","Inclusion Criteria:\n\n* Clinical diagnosis of refractory epilepsy\n* Right-handed and aged 18-50 years old and primary school education or above;\n* No major neurological or mental illness, no head injury, alcohol dependence or drug dependence;\n* During the experiment, the subjects did not smoke, drink, get sick and take psychotropic drugs, and there were no major life events that caused mood changes.\n\nExclusion Criteria:\n\n* organic brain injury, neurological diseases or serious physical diseases;\n* Have a history of substance abuse and drug dependence, or have used antipsychotic drugs in the past three months, and have serious suicidal tendencies;\n* There are contraindications for MRI or EEG or transcranial magnetic stimulation.",{"count":162,"type":21},90,[24],"To observe the clinical effect and safety of transcranial electrical stimulation on patients with refractory epilepsy before and after treatment and analyze its therapeutic mechanism.",[58,166,29,167,168],"EEG","Refractory Epilepsy","Transcranial Magnetic Stimulation",[167,29,166,170],"Transcranial magnetic stimulation","2024-02-15",{"date":173,"type":36},"2024-02-20",{"date":175,"type":21},"2024-02-12",{"date":177,"type":21},"2026-06-30",{"name":179,"class":43},"Anhui Medical University",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":104,"sex":16,"minAge":187,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":44},"100509349","orchestra-in-class-a-novel-booster-for-executive-functions-and-brain-development-in-young-primary-school-children-100509349","NCT05912270","Orchestra in Class, a Novel Booster for Executive Functions and Brain Development in Young Primary School Children","ORBIT","Inclusion Criteria:\n\n* School grade 3P\u002F4P (3rd and 4th year of elementary school (6-8-year-old children)\n* Right-handedness\n* Sufficient Mastery of the French Language\n* Able to give oral informed consent (child)\n* Able to give written informed consent (parent)\n\nExclusion Criteria:\n\n* Non-consent (children and or parents)\n* Repeated or skipped a class with respect to standard curriculum\n* Not corrected\u002Fsevere hearing deficits\n* Not corrected\u002Fsevere vision deficits\n* Severe neurodevelopmental disorders (eg. severe dyslexia, severe ADHD)\n* Older than 7 at the beginning of the school year if 3P\n* Older than 8 at the beginning of the school year if 4P\n* Protocolled music instrumental practice in the preceding year\n* Protocolled visual arts courses in the preceding year\n* MRI incompatibility (physical or psychological)\n* Psychometric battery incompatibility (psychological)","6 Years","8 Years",{"count":190,"type":21},150,[24],"How to optimally stimulate the developing brain is still unclear. Executive functions (EF) exhibited substantially stronger far transfer effects in children who learned to play a musical instrument than in children who acquired other arts.\n\nWhat is crucially lacking is a large-scale, long-term genuine randomized controlled trial (RCT) in cognitive neuroscience, comparing musical instrumental training (MIP) to another art form and a control group. Collected data of this proposal will allow, using machine learning, to build a data-driven multivariate model of children's interconnected brain and EF development over the first 2 years of their academic curriculum (6-8 years), with or without music or other art training.",[194,195,196,197,198,199,200,201,202,29,203],"Development, Child","Executive Functions","Interventions","Music","Arts","Brain Plasticity","Behavior","Brain Imaging","Magnetic Resonance Imaging","Structural Brain Connectivity","2023-12-12",{"date":206,"type":36},"2023-12-18",{"date":206,"type":21},{"date":209,"type":21},"2027-04-30",{"name":211,"class":43},"School of Health Sciences Geneva",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":227,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":238,"locationsCount":44},"100518180","randomized-controlled-study-of-optical-3d-navigated-repetitive-transcranial-magnetic-stimulation-for-achalasia-100518180","NCT06027190","Randomized Controlled Study of Optical 3D Navigated Repetitive Transcranial Magnetic Stimulation for Achalasia.","To Investigate the Clinical Efficacy of Optical 3D Navigation Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Achalasia, Optimize the Treatment Parameters, and Provide a Noninvasive Treatment Strategy for Achalasia","Inclusion Criteria:\n\n* Aged more than 18 years old, less than 75 years old;\n* Clinical symptoms evaluation, HREM, esophageal barium meal examination confirmed the diagnosis of achalasia;\n* Willing to sign informed consent.\n\nExclusion Criteria:\n\n* Presence of metal hardware in close contact with the discharge coil (e.g., cochlear implant, internal pulse generator, or drug pump). Note: Cochlear implants include electrodes, magnets, loop antennas, and electronic chips under the scalp implanted in the cochlea;\n* Intracranial metal implants;\n* Patients with cardiac pacemakers, vagal nerve stimulation (VNS) systems, spinal cord stimulators, and deep brain stimulation implanted with pulse generators should be used with caution;\n* People at higher risk of noisy hearing loss and patients with hypoacusis symptoms should be used with caution;\n* Pregnancy;\n* Severe or recent heart disease;\n* Personal history of epilepsy, use of known drugs that lower the seizure threshold, and other factors that may lower the seizure threshold (e.g., lack of sleep, infection, and alcohol abuse);\n* Increased intracranial pressure;\n* Acute phase of intracranial infection and hemorrhagic disease;\n* Contraindications to MRI examination or claustrophobia;\n* Refusal to sign informed consent.",{"count":220,"type":21},112,[24],"The goal of this clinical trial is to investigate the clinical efficacy of repetitive transcranial magnetic stimulation in the treatment of achalasia in patients diagnosed with achalasia by comprehensive evaluation of clinical symptoms, HREM, and barium meal examination, optimize rTMS treatment parameters, and provide an effective and noninvasive new treatment strategy for achalasia. The main questions it aims to answer are:\n\n1. To investigate the clinical efficacy of individualized treatment of achalasia with optical 3D navigation repetitive transcranial magnetic stimulation.\n2. Optimize rTMS parameters to achieve the best clinical treatment.\n\nParticipants will need to fill out the Eckardt score scale and SF-36 quality of life scale, undergo cranial T1 structural magnetic resonance for functional connectivity analysis, and select the brain region with the strongest positive functional connectivity to the DMV as the rTMS target. All patients were randomly divided into four groups: sham-rTMS group, 5Hz-rTMS group, 10Hz-rTMS group, and 30Hz-rTMS group, and each group received acute and chronic stimulation, respectively. In the acute stimulation stage, patients only need to do rTMS once, and HREM and HRV detection are given before and after rTMS (stimulation for 1s, interval for 4s, 10 pulses per second, receiving a total of 3000 pulses); in the chronic stimulation stage, patients receive 25 minutes of rTMS actual stimulation or sham stimulation each time, lasting for 20 times, which is completed within 30 days, and the actual stimulation parameters are the same as those of acute stimulation, and the sham stimulation coil is consistent with the appearance and sound of proper stimulation, but there is no substantial stimulation. High-definition esophageal manometry, timed barium meal, heart rate coefficient of variation, and serum neurotransmitters were performed before and after chronic stimulation. Finally, a weekly telephone follow-up was performed for 12 weeks, including Eckardt score and SF-36 quality of life scale.",[224,225,226,29],"Esophageal Achalasia","Transcranial Magnetic Stimulation, Repetitive","Vagus Nerve Motor Disorder",[228,229,230,231],"Achalasia","rTMS","fMRI","Non-invasive","2023-09-15",{"date":234,"type":36},"2023-09-21",{"date":236,"type":21},"2024-01-01",{"date":94,"type":21},{"name":239,"class":43},"Zhang Nina"]